Citi analyst Joel Beatty said he views Amarin as a “strong acquisition candidate” after the REDUCE-IT outcomes trial of Vascepa succeeded and noted that he previously stated that Amarin could be worth $14 per share in this scenario. The 25% RRR on the primary endpoint exceeded his expectations as well as that of “most bulls,” contends Beatty, who has a Buy rating and $5 price target on the stock. Near noon, Amarin shares are up 238% to $10.12.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.